Selumetinib

KOSELUGO is indicated for the treatment of adult and pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for: KOSELUGO is indicated for the treatment of adult and pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).

Side effects, and when to stop

The following clinically significant adverse reactions are described elsewhere in the labeling:

Left Ventricular Dysfunction
Ocular Toxicity
Gastrointestinal Toxicity
Skin Toxicity
Increased Creatine Phosphokinase

Who should not take it

None.

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Selumetinib; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/selumetinib
APA 7th: sofidex. (2026, August 3). Selumetinib. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/selumetinib
AMA 11th: Selumetinib. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/selumetinib

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.